TD Capital Management’s TG Therapeutics TGTX Stock Holding History

TD Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10	Closed	-$298	–	919
2025 Q4	$298	Buy	+10	New	+$327	﹤0.01%	763

Other funds holding TGTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

TD Capital Management's TGTX Position: Q1 2026 in Review

TD Capital Management sold out of TG Therapeutics (TGTX) in Q1 2026, closing a stake of 10 shares — an estimated $298 sold.

TD Capital Management first reported a position in TGTX in Q4 2025 and held it in 1 quarter. The position peaked at $298 in Q4 2025. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

TD Capital Management reported no remaining TG Therapeutics position as of Q1 2026 after selling out during the quarter.
TD Capital Management sold 10 TG Therapeutics shares in Q1 2026, an estimated $298.
TD Capital Management first reported a position in TG Therapeutics in Q4 2025 and held it in 1 quarter.
TD Capital Management's TG Therapeutics position peaked at $298 in Q4 2025.
363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on TD Capital Management's 13F filing for Q1 2026, filed 11 May 2026.